Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening tobramycin dosing in adults with cystic fibrosis
NL-OMON32697Active, not recruiting
- Sponsor
- Groene Hart Ziekenhuis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection (2 arms), sponsored by Groene Hart Ziekenhuis. Primary endpoint: Elimination rate constant. Started Jan 2009; status: active, not recruiting.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on NL-OMON32697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32697.